U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H17N3O2S.ClH
Molecular Weight 327.83
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FASUDIL HYDROCHLORIDE

SMILES

Cl.O=S(=O)(N1CCCNCC1)C2=CC=CC3=C2C=CN=C3

InChI

InChIKey=LFVPBERIVUNMGV-UHFFFAOYSA-N
InChI=1S/C14H17N3O2S.ClH/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14;/h1,3-5,7,11,15H,2,6,8-10H2;1H

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C14H17N3O2S
Molecular Weight 291.369
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Fasudil is a potent Rho kinase inhibitor, which was developed by Asahi Kasei. The drug is used in Asia for the prevention of cerebral vasospasm in patients with subarachnoid hemorrhage.

Originator

Approval Year

Unknown
134361
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8228
 0.4 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8360
ERIL

Approved Use

Improvement of cerebral vasospasm and cerebral ischemic symptoms associated with cerebral vasospasm after subarachnoid hemorrhage.
PubMed

PubMed

TitleDatePubMed
Isoquinolinesulphonamide derivatives inhibit transcriptional elongation of human immunodeficiency virus type 1 RNA in a promyelocytic model of latency.
1999 Sep
Combined administration of Fasudil hydrochloride and nitroglycerin for treatment of cerebral vasospasm.
2001
Effect of Fasudil HCl, a protein kinase inhibitor, on cerebral vasospasm.
2001
Rho-associated kinase phosphorylates MARCKS in human neuronal cells.
2001 Jan 26
Involvement of Rho-kinase in vascular remodeling caused by long-term inhibition of nitric oxide synthesis in rats.
2001 Sep 7
Enhanced contractile mechanisms in vasospasm: is endothelial dysfunction the whole story?
2002 Apr 2
Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases.
2002 Mar
Hyperosmotic-induced protein kinase N 1 activation in a vesicular compartment is dependent upon Rac1 and 3-phosphoinositide-dependent kinase 1.
2003 Aug 22
Essential role of rho kinase in the Ca2+ sensitization of prostaglandin F(2alpha)-induced contraction of rabbit aortae.
2003 Feb 1
Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm.
2003 Jan 1
A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat.
2003 Jan 3
Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice.
2003 Jul 11
Protein kinase C is necessary for recovery from the thyrotropin-releasing hormone-induced r-ERG current reduction in GH3 rat anterior pituitary cells.
2003 Mar 15
Effects of HA-1077 and Y-27632, two rho-kinase inhibitors, in the human umbilical artery.
2004
Rho-kinase expression and its contribution to the control of perfusion pressure in the isolated rat mesenteric vascular bed.
2004 Feb 6
Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms.
2004 Jan
The Rho-ROCK system as a new therapeutic target for preventing interstitial fibrosis.
2004 Jan-Feb
Role of the Rhoa/Rho kinase system in flow-related remodeling of rat mesenteric small arteries in vivo.
2004 May-Jun
Rho-kinase, a potential therapeutic target for the treatment of hypertension.
2004 Oct
Mechanisms underlying postjunctional synergism between responses of the vas deferens to noradrenaline and ATP.
2004 Sep 13
Therapeutic potential of rho-kinase inhibitors in cardiovascular diseases.
2005
Stent implantation activates RhoA in human arteries: inhibitory effect of rapamycin.
2005 Jan-Feb
High-throughput screening for kinase inhibitors.
2005 Mar
Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension.
2005 Mar 1
Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats.
2005 May
Patents

Patents

JP2003511347A
4
JPH0680569A
4
JPH0924085A
4

Sample Use Guides

In Vivo Use Guide
The recommended dosage is 30 mg fasudil hydrochloride should be diluted in 50-100 mL solution and administered by intravenous infusion over 30 minutes 2-3 times daily.
Route of Administration: Intravenous
In Vitro Use Guide
The rat aortic rings were contracted by KCl; when the contraction reached a plateau, fasudil was added at concentrations from 10(-9) to 10(-5) M. The relaxation IC50 was 0.74 uM. When rabbit aortic rings were used, IC50 values were 37,15 uM and 27,54 uM for KCl and Methoxamine-induced contraction, respectively.
Substance Class Chemical
Created
by admin
on Thu Jul 06 02:45:53 UTC 2023
Edited
by admin
on Thu Jul 06 02:45:53 UTC 2023
Record UNII
SQ04N8S7BR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FASUDIL HYDROCHLORIDE
JAN   MART.   MI   WHO-DD  
Common Name English
FASUDIL HYDROCHLORIDE [MART.]
Common Name English
1H-1,4-DIAZEPINE, HEXAHYDRO-1-(5-ISOQUINOLINYLSULFONYL)-, MONOHYDROCHLORIDE
Common Name English
Fasudil hydrochloride [WHO-DD]
Common Name English
ISOQUINOLINE, 5-((HEXAHYDRO-1H-1,4-DIAZEPIN-1-YL)SULFONYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
FASUDIL HYDROCHLORIDE [JAN]
Common Name English
FASUDIL HYDROCHLORIDE [MI]
Common Name English
5-(HEXAHYDRO-1H-1,4-DIAZEPINE-1-YLSULFONYL)ISOQUINOLINE HYDROCHLORIDE
Systematic Name English
ERIL
Brand Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 815421
Created by admin on Thu Jul 06 02:45:53 UTC 2023 , Edited by admin on Thu Jul 06 02:45:53 UTC 2023
FDA ORPHAN DRUG 715919
Created by admin on Thu Jul 06 02:45:53 UTC 2023 , Edited by admin on Thu Jul 06 02:45:53 UTC 2023
FDA ORPHAN DRUG 792720
Created by admin on Thu Jul 06 02:45:53 UTC 2023 , Edited by admin on Thu Jul 06 02:45:53 UTC 2023
FDA ORPHAN DRUG 936123
Created by admin on Thu Jul 06 02:45:53 UTC 2023 , Edited by admin on Thu Jul 06 02:45:53 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID1045615
Created by admin on Thu Jul 06 02:45:53 UTC 2023 , Edited by admin on Thu Jul 06 02:45:53 UTC 2023
PRIMARY
PUBCHEM
163751
Created by admin on Thu Jul 06 02:45:53 UTC 2023 , Edited by admin on Thu Jul 06 02:45:53 UTC 2023
PRIMARY
MERCK INDEX
M5249
Created by admin on Thu Jul 06 02:45:53 UTC 2023 , Edited by admin on Thu Jul 06 02:45:53 UTC 2023
PRIMARY Merck Index
DRUG BANK
DBSALT002399
Created by admin on Thu Jul 06 02:45:53 UTC 2023 , Edited by admin on Thu Jul 06 02:45:53 UTC 2023
PRIMARY
CAS
105628-07-7
Created by admin on Thu Jul 06 02:45:53 UTC 2023 , Edited by admin on Thu Jul 06 02:45:53 UTC 2023
PRIMARY
MESH
C049347
Created by admin on Thu Jul 06 02:45:53 UTC 2023 , Edited by admin on Thu Jul 06 02:45:53 UTC 2023
PRIMARY
SMS_ID
100000088231
Created by admin on Thu Jul 06 02:45:53 UTC 2023 , Edited by admin on Thu Jul 06 02:45:53 UTC 2023
PRIMARY
FDA UNII
SQ04N8S7BR
Created by admin on Thu Jul 06 02:45:53 UTC 2023 , Edited by admin on Thu Jul 06 02:45:53 UTC 2023
PRIMARY
EVMPD
SUB21642
Created by admin on Thu Jul 06 02:45:53 UTC 2023 , Edited by admin on Thu Jul 06 02:45:53 UTC 2023
PRIMARY
Related Record Type Details
Structure of FASUDIL HYDROCHLORIDE HEMIHYDRATE
SOLVATE->ANHYDROUS
Structure of FASUDIL
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of FASUDIL
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966